Ore Pharmaceuticals Inc. company was founded in 1994 and is headquartered in Cambridge, Massachusetts. Ore Pharmaceutical Holdings Inc., through its wholly owned subsidiary, Ore Pharmaceuticals Inc., operates as a drug development company in the United States. Its drug candidates include GL1001, the lead drug candidate that completed a multiple ascending dose Phase I clinical trial, for the treatment of inflammatory bowel disease; tiapamil for treatment of diseases of central nervous system, primarily focused on cognition and memory; and romazarit, a clinical-stage drug candidate for the treatment of metabolic indications, such as obesity.

Ash Stevens, Inc. was founded in 1962 to provide chemical research for the government and later branched out into the private sector. Ash Stevens, Inc. company, a contract pharmaceutical manufacturer develops and manufactures active pharmaceutical ingredients (APIs) for other pharmaceutical companies. It also supports clinical drug trials and helps others navigate the FDA's regulatory maze. Its customers include the federal government and commercial pharmaceutical firms. The company's portfolio includes about a dozen FDA-approved drug components.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Tridelta specialises in the development, manufacturing and marketing of diagnostic products for the animal health care industry. The company has commercialised five technologies to date with its "PHASE" range of Acute Phase Protein Assays, which are indicators of the presence of an inflammatory reaction, detected in the blood before the animal shows any physical signs of ill health. Species of specific interest include: cattle, horses, sheep, cats, dogs, pigs and rodents.

Eczacibasi Pharmaceutical and Industrial Investment (formerly Eczacibasi Pharmaceuticals Manufacturing) helps to keep the residents of Turkey healthy. The company provides a variety of pharmaceutical and health care products, including vitamins, diagnostic substances, and personal care items. Eczacibasi Pharmaceutical has interests in prescription drug marketing and manufacturing firms, as well as health care supply distribution firms. It also sells generic drugs through a partnership with Zentiva (part of Sanofi-Aventis). The firm's real estate division invests in commercial properties. Founded in 1952, Eczacibasi Pharmaceutical is a subsidiary of family owned Turkish industrial group Eczacibasi Holding.

Nature's Sunshine Products, Inc. company was founded in 1972 and is based in Provo, Utah. Nature's Sunshine Products, Inc., together with its subsidiaries, engages in the manufacture and marketing of nutritional and personal care products worldwide. The company offers herbal products in the form of capsules or tablets; single herbs and herb combinations in the form of liquid herbs and extracts; vitamins and mineral supplements in the form of chewable or non-chewable tablets; personal care products, including oils and lotions, aloe vera gel, herbal shampoo, herbal skin treatment, toothpaste, and skin cleanser; and various other products, such as nutritional drinks, homeopathic products, and powders. Nature's Sunshine Products sells its products to a sales force of independent distributors and managers, who use the products themselves or resell them to other distributors or consumers. It also exports its products to various countries, including Argentina, Australia, Chile, New Zealand, and Norway.

Founded in 1926, Recordati S.p.A. company makes prescription and nonprescription pharmaceuticals and active pharmaceutical ingredients (APIs). Its prescription drug business includes antibiotics and antiviral drugs, as well as treatments for cardiovascular, central nervous system, dermatological, gynecology, urological, and other disorders and ailments. Over-the-counter products include remedies for allergies and colds, travel sickness, and fungal infections. Recordati company has subsidiaries and direct sales representatives located in about a dozen European countries. Recordati's products are distributed in some 100 countries.

Fulcrum Pharma plc is a United Kingdom-based company. The Company is engaged in providing solutions for the development of therapeutic products. It provides regulatory expertise and resource throughout all stages of product development. The Company provides customized pharmacovigilance and risk management solutions. It provides support for product registration, launch and in market maintenance. It operates through eight offices across the United States, Europe and Japan. The Company’s subsidiaries include Fulcrum Pharma (Europe) Limited, Fulcrum Pharma Developments Limited, Quadramed Limited, Unicus Limited and Fulcrum Regulatory Limited.

H. Lundbeck develops medicine primarily for the treatment of diseases of the central nervous system. Sold throughout the world, Lundbeck's main products include Cipralex (licensed to Forest Laboratories in the US market under the brand Lexapro) for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer's disease, and Azilect for the treatment of Parkinson's disease. Lundbeck spends about 20% of its revenue on research and development. The company has additional licensing and collaborative agreements with other drug makers including Teva Pharmaceuticals, Takeda, Merz, and Solvay.

Inovio Biomedical Corporation was founded in 1983 and is based in San Diego, California. Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company's SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovio's proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovio's clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, NIH Vaccine Research Center, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.